J o u r n a l P r e -p r o o f 3 support a core concept of the illness as a primary disorder in mood, in particular a lowering in mood that is embodied in the individual, though we would not expect perfect classification with current diagnostic criteria (4).
We propose that neuroimaging can aid in identifying potential biotypes by quantifying the heterogeneity, as well as homogeneity, that comprise major depression and the biotypes that can predict clinical outcome. We review development from the initial studies 10 years ago, which had applied machine learning to neuroimaging data to classify major depression and to predict clinical outcome (4) (5) (6) , to replication and progression in international independent datasets (7) (8) (9) , and how heterogeneity is being addressed in recent studies (7, 10, 11). We review homogeneous mechanisms in psychological and pharmacological therapies, and we discuss the potential to identify biomarkers to predict clinical response.
We propose that multitudinous heterogeneous symptom profiles can arise from a limited number of neural patterns as well as how apparently heterogeneous clinical outcomes can include a common baseline predictor of response and common mechanism of treatment.
We conclude with a proposal for the necessary steps and recent developments to identify neuroimaging-based biotypes: 1) harmonization of longitudinal multisite datasets acquired in different scanners and with different image acquisition protocols (12) ; 2) modelling the pathological process by multiple regularized transformations from the healthy to the patient population to identify the multiple neuroanatomical patterns that characterise disease heterogeneity (CHIMERA) (13) ; and 3) characterisation of the neuroanatomical J o u r n a l P r e -p r o o f spatially distributed alterations into models, learning to categorise the patterns and then to identify them in new data. Applying machine learning, proof of concept data demonstrated the ability to identify major depression at the level of the individual with high sensitivity and specificity from structural MRI and task-based functional MRI data (5, 6, 25) , and distinct models predicted clinical response at baseline before the start of treatment with measures of confidence of the accuracy of the predictions (26) . Kambeitz et al. (8) meta-analysis of 33 international samples of major depression (n = 912) and healthy (n = 864) participants demonstrated an overall classification with 77% sensitivity and 78% specificity, based on structural MRI, resting state functional MRI, task-based functional MRI and diffusion tensor imaging. Most studies to date have generated dichotomous classification labels for diagnosis, either major depression or healthy control, primarily due to limited sample sizes of participants with major depression (n = 15-57) (8, 9).
In the largest multisite sample to date, Drysdale et al. (7) were able to identify a number of subtype models based on resting state functional MRI data, which were then validated in independent samples. The models were developed from what would be considered a more treatment-resistant form of depression, that is from participants with major depression (n = 220) with active symptoms which had failed to respond to at least two antidepressant treatment trials and while taking medications. The models were then trained in the full sample of depression (n = 333) and healthy (n = 378) participants and further validated in independent samples of depression (n = 125) and healthy (n = 352) participants.
J o u r n a l P r e -p r o o f 6 highest levels of anxiety, early and middle insomnia, as well as anhedonia. The subtypes were not accounted for by depressive severity only as there were no significant differences in depressive severity scores in subtypes 1, 3 and 4, although there was a modest decrease in subtype 2. Increased thalamic and frontostriatal connectivity associated with anhedonia and psychomotor retardation was most pronounced in subtypes 3 and 4. Reduced frontoamygdala connectivity associated with anxiety was most severe in subtypes 1 and 4.
Reduced connectivity in anterior cingulate and orbitofrontal regions involved in motivation associated with symptoms of anergia and fatigue were most evident in subtypes 1 and 2.
By addressing heterogeneity, Drysdale et al. (7) represent an important step in identifying potential biotypes that comprise major depression.
While the highest levels of sensitivity and specificity in classification have been achieved in the treatment-resistant form of depression (8, 9) , these could be confounded by biological effects of treatment resistance and antidepressant medication on brain structure and function (27, 28) . From a methodological perspective, Dinga et al. (29) suggest that the clustering algorithm had led to overfitting as their replication analysis could not generate comparable statistically significant subtypes. However, the samples differ significantly in their clinical characteristics in terms of treatment resistance and depressive state, which are associated with distinct neural correlates (27, 28) . Drysdale et al. (7) training sample had been based on treatment resistant depression in an acute episode, while Dinga et al. (29) sample (n = 178) was comprised of major depression, anxiety disorders, as well as comorbid depression and anxiety disorders, in which about half the sample were in remission or had mild symptoms. The training samples, while larger than the majority of studies to date, could have been sufficiently non-overlapping, were underpowered, and might reflect homogeneity in the neural biotypes of less treatment resistant forms of the illness that are in remission or with few symptoms and which present as heterogeneous clinical phenotypes (7, 29) .
Journal Pre-proof J o u r n a l P r e -p r o o f Heterogeneity in methodology is a controllable variable. Task-based functional MRI protocols focused on a cognitive task (25) show lower levels of classification accuracy relative to an emotion-based task (5), which is not unexpected in major depression.
Overlooking task effects adds variability that is not random, which degrades the quality of the signal and introduces confounds in meta-analyses of classification biomarkers (8, 36) .
Heterogeneity (and homogeneity) in treatment mechanisms
Selective serotonin reuptake inhibitor (SSRI) antidepressants enhance synaptic plasticity, in which the effects on mood might be moderated by environment (37, 38). Pharmacological treatment is associated with increases in regional cerebral volumes, such as in the hippocampus (39). Hippocampal volume is reduced in major depression, which is evident in the first episode (23) . SSRI treatment is associated with increased hippocampal volume (39), and an early increase in hippocampal volume following one week of treatment with a serotonin noradrenaline reuptake inhibitor (SNRI) antidepressant was predictive of clinical response (40) , which could reflect enhancement in synaptic plasticity and neurogenesis (37, 38).
Psychotherapy is an effective treatment for an acute depressive episode, is the preferred form of treatment for many individuals with depression, and demonstrates a sustained benefit in preventing a subsequent depressive relapse (41) (42) (43) . The most common forms of Journal Pre-proof J o u r n a l P r e -p r o o f 9 short term psychotherapy are cognitive behavior therapy, behavioral activation, interpersonal therapy, and psychodynamic psychotherapy. Distinct formulations and mechanisms have been proposed, however efficacy has either been comparable or no significant differences have been observed between treatments (44-47). Moreover, our understanding of the neural mechanisms is limited, and there have been remarkably few longitudinal studies of the neural correlates of psychotherapy in depression, about a quarter of the number of pharmacological studies (48, 49) .
The theoretical formulation of cognitive behavior therapy (CBT) proposes a cognitive triad of biased negative views of onself, one's future and experiences in the outside world which leads to characteristic affective and behavioural symptoms (50) . CBT attempts to intervene in this cycle by addressing negative cognitions: automatic thoughts (eg. "I'm a failure") and dysfunctional attitudes (eg. "I should be happy all the time") that in turn reflect schemas and core beliefs which organize new experiences. Cognitive change is a key mechanism in which modifying maladaptive cognitions leads to an improvement in mood (50) . Behavioral activation therapy focuses on behavioural change to increase engagement in constructive reinforcing activities and to reduce engagement in avoidance and withdrawal behaviours which maintain depression. Behavioral activation refers to the process of changing behaviors in order to engage in positively reinforcing and adaptive activities, which has demonstrated efficacy as a stand-alone component of CBT (51) (52) (53) .
Interpersonal therapy (IPT) is based on the premise that maladaptive communication processes impact negatively on mood. IPT seeks to address interpersonal difficulties common in depression, focusing on four main themes: bereavement related to the grief and loss of a significant other; role transition due to a life change which affects relationships, such as a new job or loss of functioning; interpersonal disputes in expectations in relationships with significant others; or interpersonal deficits which could be reflected in social isolation or difficulties in maintaining relationships (46, 54) . Short term psychodynamic Journal Pre-proof J o u r n a l P r e -p r o o f psychotherapy applies support as well as insight to discuss internalized past relationships, intrapersonal patterns and current relationships. Psychodynamic psychotherapy considers how internalized past relationships and unconscious processes could impact on interpersonal relationships and day to day functioning to improve awareness of such processes which in turn aids in the ability to modify responses and behaviours in current behaviours and relationships (47, 55) .
If a particular process is a mechanism, it is necessary to establish the temporal sequence such it is the specific process which leads to improvements in depressive symptoms (56) . As a potential mechanism in CBT, a change in cognition would be expected to precede any improvements in depressive symptoms. In support, early changes in cognition during CBT and "sudden gains" (57-59) as well as therapist adherence to techniques and competence (60) are associated with symptom improvements. However, when changes in mood symptoms were taken into account, early changes in cognitive content no longer predicted subsequent improvements (61) . Moreover, improvements in depressive symptoms have also been observed to precede changes in cognitions (62) . Component analysis suggests that the effectiveness of CBT can be largely ascribed to behavioral activation (51, 52), while acknowledging a predictive component of cognitive change, though assessed as a nominal contribution (63) .
Although heterogeneous mechanisms have been proposed, the effects are small (44) (45) (46) (47) . It is well established that common factors contribute to the efficacy of the different forms of psychotherapy. Therapeutic alliance refers to the relationship between the patient and therapist and has consistently demonstrated a mediating effect in clinical outcome to psychotherapy (59, 60) , as well as to pharmacological and placebo treatments (64, 65) .
Patient outcome expectations describe the prognostic beliefs about effects of engaging in treatment that could be positive, negative or ambivalent, which show a small association with treatment outcome, which may further be mediated by the therapeutic alliance (66) . A J o u r n a l P r e -p r o o f 11 common role of the therapist in short term psychotherapy is as an advocate for the patient.
The CBT therapist is proposed to represent an active, authoritative advocate for change who supports patients to engage in activities and thoughts, which in turn leads to improvements in depressive symptoms (63) . The goal of the IPT therapist is to be the patient's ally who reinforces beneficial interpersonal skills and actively reviews adverse outcomes including through role play and rehearsal (46, 54) . A range of outcomes has been observed between therapists, in which adherence and competence seem to have a limited effect (67), while therapist adaptiveness and empathy are correlated with clinical outcome (68) . How, when and what a therapist responds to in a session reflects their adaptiveness and empathy.
Enhanced synaptic plasticity is a potential common mechanism of antidepressant medication (37, 38) and psychotherapy. Synaptic plasticity is a fundamental mechanism in learning and memory (57) (58) , and learning is an important mechanism in psychotherapy, in which the therapist provides an essential component with whom skills are learned. Moreover, we propose that the patient therapist relationship builds upon inherent models of relationships.
Even in the absence of a therapist who is physically present, we would expect that inherent models would have an impact on the perceived relationship, such as in internet-based treatments. We propose that encoding of the relationship is episodic with the repeated sessions of the therapy and that recall of the relationship may be initially explicit. Limited development of inherent models of interpersonal relationships could also be associated with genetic risk load, for example it might be expected that patients with depression with a high genetic risk load for autistic spectrum disorder would prefer an internet based CBT, however, if they have an impaired inherent model of interpersonal relationships, then their ability to interact with and utilise the CBT format would be limited (71) , as potentially for any short term therapy which could be transdiagnostic.
Shared features in the forms of therapy include treatment durations, which have mostly been short term in the order of weeks to months, low rates of clinical effectiveness, and the role of the therapist as an active advocate who interacts directly with the patient (72) (73) (74) . However, if the ability of the patient to engage with the therapist depends in part on their inherent models of interpersonal relationships, then impairments in the models would impact on how their relationship develops with the therapist, to which some therapists may be better able to respond and adapt their treatment. This heterogeneity could be evident in part in amygdala responsivity, for example an insecure anxious attachment pattern is associated with increased amygdala response to emotional stimuli (75) and attachment patterns modulate experimentally induced pain ratings in the presence of an observer (76).
Addressing heterogeneity
Being able to identify an acute depressive episode in major depression that is not treatmentresistant, to predict treatment outcome and to predict the course of the illness are key clinical challenges. Model development requires the appropriate data and methodology, which can J o u r n a l P r e -p r o o f 14 be summarised, but the quality of the data and methodology are paramount (4, 10) . In order to reflect clinical practice and to develop models that are not confounded by treatment, the data would be from a community based medication-free population in an acute depressive episode with first episode or recurrent depression that is not treatment-resistant. Well characterised large datasets are required with consideration of ethical and data sharing issues. We would not expect perfect classification with current diagnostic criteria because clinical presentations do not necessarily reflect specific biological measures and do not identify specific pathophysiologies. We would expect an iterative process in which the neuroimaging-based biomarkers are applied to specify potential pathophysiologies (4).
Methods that directly address heterogeneity are essential. Several studies have begun to use high-dimensional clustering methods to dissect imaging heterogeneity in various diseases (77) . While direct clustering of patient data can be informative, it is confounded by variations related to demographics and other factors that are not related to dis ease pathophysiology. Two semi-supervised learning methods are proposed in an attempt to address this limitation: CHIMERA (13) and HYDRA (14) .
CHIMERA is primarily generative, and it assumes that the statistical distribution of imaging features of the (heterogeneous) patient cohort is derived from the statistical distribution of the healthy cohort via a number of transformations that reflect the effects of underlying In summary, neuroimaging-based biomarkers offer the strongest potential to date in identifying the biotypes that comprise our current symptom-based diagnosis of major depression. Increasing sample sizes from multisite collaborations will provide increased power to identify neural biotypes that comprise the diagnosis. Among purported heterogeneous treatment mechanisms, a common factor is the patient clinician relationship. The HYDRA method is mostly discriminative, in that it attempts to separate patients and controls as well as possible, using multiple hyperplanes, one for each subtype. 
